Dec 13, 2017
Dr Andrew Saunders has left Lytix Biopharma

Dr Andrew Saunders has decided to leave the company after 3 years as Chief Medical Officer (CMO).

Dr. Saunders commented: 

“It has been a pleasure to work with great colleagues at Lytix on LTX-315 in the exciting area of immune-oncology.”

Gert Munthe, Chairman of the board commented:

 “ Dr. Saunders has provided excellent clinical and strategic leadership during his time at Lytix
               and the company greatly appreciates his hard work and wishes him well for the future.”   

Dr. Edwin Klumper, will act as both CEO and CMO as of December 13th 2017.